BioN­Tech touts dif­fer­ences with Mod­er­na in race for can­cer vac­cines

BioN­Tech chief strat­e­gy of­fi­cer Ryan Richard­son high­light­ed the dif­fer­ences be­tween his com­pa­ny’s can­cer vac­cine and an­oth­er un­der de­vel­op­ment by Mod­er­na and Mer­ck, as the com­pa­nies race each oth­er for a piece of what could be a ma­jor new class of prod­ucts.

Richard­son spoke at an in­vest­ment con­fer­ence host­ed last week by SVB Se­cu­ri­ties and his com­ments were de­scribed in an an­a­lyst note.

BioN­Tech has sev­er­al mR­NA can­cer can­di­dates in the works, in­clud­ing for ad­vanced melanoma, ovar­i­an can­cer and non-small cell lung can­cer, ac­cord­ing to its web­site. The ri­val­ry with Mod­er­na and Mer­ck is fo­cused around its in­di­vid­u­al­ized vac­cine, RO7198457 (al­so known as BNT122), which it calls an in­di­vid­u­al­ized Neoanti­gen Spe­cif­ic im­munoTher­a­py, or iN­eST. It’s de­vel­op­ing the vac­cine with Genen­tech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER